BALA CYNWYD, Pa., Oct. 31, 2007 (PRIME NEWSWIRE) -- Duska Therapeutics, Inc., (OTCBB:DSKA), a biopharmaceutical company developing new medicines to treat cardiovascular diseases, announced today that it has appointed Alan J. Tuchman, M.D., M.B.A., as a board director.
Dr. Tuchman is Executive Chairman of Neurophysics, Inc., a medical technology company. He is also a partner in Xmark Opportunity Partners, a biotech investment fund. Dr. Tuchman is Clinical Professor of Neurology and Pharmacology at New York Medical College and the author of over 30 scientific papers and book chapters. He serves on the Scientific Advisory Board of Oncolytics Biotech, Inc., and was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his medical degree from the University of Cincinnati, College of Medicine, and completed his neurology residency at the Mt. Sinai School of Medicine. He received his M.B.A. from Columbia University.
"With our pipeline of products, Dr. Tuchman's background as a biotech investor and clinical professor of neurology and pharmacology will provide excellent guidance to the company as a board director," stated Dr. James S. Kuo, Duska's Chairman and CEO.
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc., develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPace(tm), (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website at www.duskatherapeutics.com.
Forward-Looking Statement: This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and certainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of Duska's drug development projects, Duska's limited financial resources and its need to raise additional capital to fund its ongoing working capital and drug development needs, the need for future clinical testing of Duska's drug candidates, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for Duska's P2R technologies, risks relating to the enforceability of any patents covering Duska's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for Duska's products. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. All forward-looking statements are based upon information available to Duska on the date the statements are first published. Duska undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.